

May 1, 2008

APA DSM-V Work Group Member

Name, Degree: Bridget F. Grant, Ph.D.

Role(s) in Work Group: Member, Substance-Related Disorders Work Group

Institutional Affiliation(s): Natl Inst of Health, Natl Inst on Alcohol Abuse and Alcoholism

City, State: Rockville, MD

Biographical Sketch:

Dr. Grant is Chief of the laboratory of epidemiology and biometry and the National Institute on Alcohol Abuse and Alcoholism. She has earned Doctoral Degrees in both Psychology and Psychiatric Epidemiology. Her work over the last 20 years has focused on the epidemiology of alcohol, drug and mental disorders. Dr. Grant has also published widely in the area of psychiatric nosology; and has participated in some capacity in the DSM-IIIIR, DSM-IV, and the ICD-10. She is the recipient of the 2007 Jellinek Memorial Award, for her contributions to the alcohol and drug field and comorbidity. This is the highest international recognition in the alcohol field.

UNCOMPENSATED AFFILIATIONS WITH NON-PROFIT OR ADVOCACY ORGANIZATIONS THAT MAY HAVE A DIRECT OR INDIRECT INTEREST IN PSYCHIATRIC DIAGNOSIS, TREATMENT, OR THE DSM-V : CALENDAR YEARS 2005, 2006, 2007, AND FOR 2008, ACTIVITIES TO DATE AND COMMITMENTS FOR REMAINDER OF YEAR.

Non-Profit and Advocacy Organizations	Year(s)	Role
None		

The two tables below represent Dr. Grant's disclosure of significant interests and affiliations for: (1) The full calendar years of 2005, 2006, and 2007; and (2) for 2008, interests and affiliations to date and commitments for remainder of the year.

Dr. Grant has agreed that, from the time of approval through the publication of DSM-V, projected in 2012, (his/her) aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed \$10,000 in any calendar year.

<p>KEY NUMBER:</p> <p>1. Consultation Fees (include scientific advisory boards)</p> <p>2. Full- or Part-time Employee</p> <p>3. Industry-related Grant-Research Support received or pending</p> <p>4. Honoraria (includes Speakers' Bureau)</p> <p>5. Stock or other financial options</p>	<p>6. Expert testimony</p> <p>7. Royalties (including right to share of revenue or profit from pharmaceutical, device or other development or product)</p> <p>8. Patents received or pending</p> <p>9. Officer, director/trustee, executive (specify)</p> <p>10. Other (specify)</p>
---	--

UPDATED 4.28.08

DISCLOSURE OF SIGNIFICANT INTERESTS FOR 2005, 2006, AND 2007

Commercial or Other Organization	Year(s)	Key #(s)
None		

DISCLOSURE OF SIGNIFICANT INTERESTS TO DATE FOR 2008 AND COMMITMENTS FOR REMAINDER OF YEAR

Commercial or Other Organization	Year(s)	Key #(s)
None		